[Clinical studies on S 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections].
S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg divided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80%. There were no side effects of abnormal laboratory findings due to administration of this drug.
Aonuma
S
S
Department of Internal Medicine, Tohoku University.
Oizumi
K
K
Watanabe
A
A
Tokue
Y
Y
Honda
Y
Y
Ono
R
R
Kitamura
N
N
Konno
K
K
Satoh
K
K
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002433:Cefaclor / Q000008:administration & dosage / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D002433:Cefaclor; D002506:Cephalexin